Ocrevus Subcutaneous: Valuing the benefits to people living with MS, whānau caregivers, and the health system
Multiple Sclerosis New Zealand (MSNZ) welcomes this timely and evidence-based report from NZIER, commissioned by Roche Products NZ. Representing 18 member organisations and over 5,000 New Zealanders living with MS, along with their whānau, carers and supporters, MSNZ has long advocated for equitable access to life-changing treatments. Over the past decade, therapies like ocrelizumab have […]
Ocrelizumab Subcut Receives Medsafe Registration as Pressure Mounts to Fund Wider Range of MS Treatment Options
Photo by Kristine Wook, Unsplash. Medsafe have approved the registration of Ocrevus ® Subcutaneous (SC) (ocrelizumab and hyaluronidase) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The announcement on 24th April is welcomed by Multiple Sclerosis New Zealand. “The registration of Ocrevus SC is […]
Are you on an Infusion Treatment?
At MSNZ we would like to understand more about patient experiences with infusion treatments. The first line Disease Modifying Treatment (DMT) options we have been successful in advocating for in NZ are considered some of the best in the world. Due to the availability of these treatments and adopting healthy lifestyle recommendations, people are reportedly […]